INNOVATION EXCELLENCE IN RESEARCH
WINNER: Avalia Immunotherapies
Sponsored by Callaghan Innovation
Avalia Immunotherapies develops vaccines that activate powerful immune cells in order to treat diseases.
Avalia Immunotherapies is an immuno-oncology company that develops vaccines that activate a family of immune cells called ‘Natural Killer T-Cells’ (NKT Cells) to trigger a powerful immune response to treat, and prevent, disease. Avalia focuses on therapeutic vaccines for the treatment of human papillomavirus (HPV), as the available prophylactic vaccines are ineffective against existing infections, and existing pre-cancer treatments are unsuitable for many individuals or lapse after a couple of years. Avalia triggers longer term anti-tumour immune responses in patients, making it more effective than other options. In many cases, HPV can be killed off by the body’s own natural immune response, and Avalia enhances that ability.
Highly Commended: Alliance Group - The Omega Lamb Project